Click here to close now.


News Feed Item

The Leukemia & Lymphoma Society Awards $12.6 Million in Research Grants in Six Critical Areas of Unmet Medical Need

WHITE PLAINS, N.Y., Jan. 6, 2014 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) has awarded 21 new grants representing a total investment of $12.6 million to tackle six areas of high unmet medical need in the blood cancers.

In response to requests for proposals (RFPs) from researchers in these six critical areas, LLS has awarded these grants under its Translational Research Program (TRP), an initiative designed to help accelerate the movement of promising discoveries from the lab to the clinic. Each grant is for a three-year duration with a total value of $600,000.

The RFPs mark LLS's proactive approach to addressing the challenge of improving outcomes for cancer patients with particularly urgent needs. The focus of the TRP grants, and the grant recipients are as follows:

  • New immunotherapeutics for patients with acute myelogenous leukemia (AML):

    • David Avigan, M.D., Beth Israel Deaconess Medical Center. Clinical trial evaluating DC/AML fusion vaccine with PD1 blockade
    • Stephen Forman, M.D., Beckman Research Institute of the City of Hope. Adoptive therapy for AML using CAR123-transduced T cells
    • Dean Lee, M.D., Ph.D., University of Texas MD Anderson Cancer Center. Targeting NK cell immunotherapy against AML stem cells.
    • Ulrich Steidl, M.D., Ph.D., Albert Einstein College of Medicine of Yeshiva University. Targeting IL-1 receptor accessory protein in malignant stem cells in AML
    • Chengcheng Zhang, Ph.D., UT Southwestern Medical Center. Blocking immune inhibitory receptor LAIR1 for AML treatment

  • Novel therapeutics for patients with non-cutaneous T-cell malignancies:

    • Thomas Loughran, M.D., The Pennsylvania State University College of Medicine. Targeting JAK/STAT and NF-kB pathways in large granular lymphocytic leukemia
    • David Wiest, Ph.D., Fox Chase Cancer Center, Role of ER stress responses in pathogenesis and treatment of T-cell acute lymphocytic leukemia
    • Javeed Iqbal, Ph.D., Board of Regents of the University of Nebraska Medical Center. Somatic mutations and epimutations in peripheral T-cell lymphoma

  • Introduction of novel agents in the treatment of patients with diffuse large B-cell lymphom(DLBCL) and mantle cell lymphoma(MCL):

    • Robert Baiocchi, M.D., Ph.D., The Ohio State University Research Foundation. Targeting PRMT5 expression in DLBCL and MCL
    • Leandro Cerchietti, M.D., Joan & Sanford I. Weill Cornell Medical College of Cornell University. EIF4E targeted therapy in lymphomas
    • Ari Melnick, M.D., Joan & Sanford I. Weill Cornell Medical College of Cornell University. Rational translational of EZH2 targeted therapy
    • Alessandra Pernis, M.D., The Hospital for Special Surgery. Novel signaling pathways in DLBCL
    • James Rubenstein, M.D., Ph.D., The Regents of the University of California, San Francisco. Molecular targets for high-risk primary CNS lymphoma
    • John Timmerman, M.D., The Regents of the University of California, Los Angeles. PD-1/PD-L1 blockade plus kinase inhibitor therapies for B cell lymphomas

  • Therapies for patients with myelodysplastic syndromes(MDS) who have failed hypomethylating agents:

    • Maria Figueroa, M.D., University of Michigan Health System, Epigenetic markers of sensitivity and resistance to hypomethylating agents

  • Therapies for new targets such as bromodomains, methylation and other epigenetic approaches for patients with high-risk myeloma:

    • Xiu-Bao Chang, Ph.D., Mayo Clinic Arizona. Immunomodulatory drugs target cereblon and its downstream substrates
    • Constantine Mitsiades, M.D., Ph.D., Dana-Farber Cancer Institute. Individualizing myeloma treatment with BET bromodomain inhibitors

  • Research that addresses long-term and late effects of blood cancer therapies:

    • Mukta Arora, M.D., Regents of the University of Minnesota, Twin Cities. Biomarkers of frailty and its impact on geriatric HSCT outcomes
    • Seth Corey, M.D., Northwestern UniversityChicago campus. Development of an oral anti-fibrotic drug for patients with myelofibrosis
    • Patricia Gallagher, Ph.D., Wake Forest University Health Sciences. Prevention of doxorubicin-induced cardiotoxic late effects by Ang-(1-7)
    • Matthew Matasar, M.D., Memorial Sloan-Kettering Cancer Center. Tissue and functional assessment of myocardial injury in HL survivors

LLS also announced the awarding of an additional 20 TRP grants not related to the RFPs, totaling $11.4 million, to scientists working in other areas of blood cancer research.

"The translation of research discoveries in the laboratory to the patient's bedside for the treatment of blood cancer is a central part of the mission of LLS," said Lee Greenberger, Ph.D., LLS chief scientific officer. "By taking a strategic, proactive approach, LLS is directing grant funds with the intent to accelerate the advancement of breakthrough therapies and provide the best quality of life for our patients."

About The Leukemia & Lymphoma Society
The Leukemia & Lymphoma Society ® (LLS) is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, multiple myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world, provides free information and support services, and is the voice for all blood cancer patients seeking access to quality, affordable, coordinated care.  

Founded in 1949 and headquartered in White Plains, NY, LLS has chapters throughout the United States and Canada. To learn more, visit Patients should contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET.

Contact: Andrea Greif
(914) 821-8958
[email protected]


SOURCE The Leukemia & Lymphoma Society

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
This week, the team assembled in NYC for @Cloud Expo 2015 and @ThingsExpo 2015. For the past four years, this has been a must-attend event for MetraTech. We were happy to once again join industry visionaries, colleagues, customers and even competitors to share and explore the ways in which the Internet of Things (IoT) will impact our industry. Over the course of the show, we discussed the types of challenges we will collectively need to solve to capitalize on the opportunity IoT presents.
As more intelligent IoT applications shift into gear, they’re merging into the ever-increasing traffic flow of the Internet. It won’t be long before we experience bottlenecks, as IoT traffic peaks during rush hours. Organizations that are unprepared will find themselves by the side of the road unable to cross back into the fast lane. As billions of new devices begin to communicate and exchange data – will your infrastructure be scalable enough to handle this new interconnected world?
Containers are all the rage among developers and web companies, but they also represent two very substantial benefits to larger organizations. First, they have the potential to dramatically accelerate the application lifecycle from software builds and testing to deployment and upgrades. Second they represent the first truly hybrid-approach to consuming infrastructure, allowing organizations to run the same workloads on any cloud, virtual machine or physical server. Together, they represent a ver...
As operational failure becomes more acceptable to discuss within the software industry, the necessity for holding constructive, actionable postmortems increases. But most of what we know about postmortems from "pop culture" isn't actually relevant for the software systems we work on and within. In his session at DevOps Summit, J. Paul Reed will look at postmortem pitfalls, techniques, and tools you'll be able to take back to your own environment so they will be able to lay the foundations for h...
SYS-CON Events announced today the Containers & Microservices Bootcamp, being held November 3-4, 2015, in conjunction with 17th Cloud Expo, @ThingsExpo, and @DevOpsSummit at the Santa Clara Convention Center in Santa Clara, CA. This is your chance to get started with the latest technology in the industry. Combined with real-world scenarios and use cases, the Containers and Microservices Bootcamp, led by Janakiram MSV, a Microsoft Regional Director, will include presentations as well as hands-on...
SYS-CON Events announced today that Dyn, the worldwide leader in Internet Performance, will exhibit at SYS-CON's 17th International Cloud Expo®, which will take place on November 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. Dyn is a cloud-based Internet Performance company. Dyn helps companies monitor, control, and optimize online infrastructure for an exceptional end-user experience. Through a world-class network and unrivaled, objective intelligence into Internet condit...
SYS-CON Events announced today that Sandy Carter, IBM General Manager Cloud Ecosystem and Developers, and a Social Business Evangelist, will keynote at the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA.
Saviynt Inc. has announced the availability of the next release of Saviynt for AWS. The comprehensive security and compliance solution provides a Command-and-Control center to gain visibility into risks in AWS, enforce real-time protection of critical workloads as well as data and automate access life-cycle governance. The solution enables AWS customers to meet their compliance mandates such as ITAR, SOX, PCI, etc. by including an extensive risk and controls library to detect known threats and b...
DevOps Summit, taking place at the Santa Clara Convention Center in Santa Clara, CA, and Javits Center in New York City, is co-located with 17th Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to wait...
Overgrown applications have given way to modular applications, driven by the need to break larger problems into smaller problems. Similarly large monolithic development processes have been forced to be broken into smaller agile development cycles. Looking at trends in software development, microservices architectures meet the same demands. Additional benefits of microservices architectures are compartmentalization and a limited impact of service failure versus a complete software malfunction....
The last decade was about virtual machines, but the next one is about containers. Containers enable a service to run on any host at any time. Traditional tools are starting to show cracks because they were not designed for this level of application portability. Now is the time to look at new ways to deploy and manage applications at scale. In his session at @DevOpsSummit, Brian “Redbeard” Harrington, a principal architect at CoreOS, will examine how CoreOS helps teams run in production. Attende...
DevOps and Continuous Delivery software provider XebiaLabs has announced it has been selected to join the Amazon Web Services (AWS) DevOps Competency partner program. The program is designed to highlight software vendors like XebiaLabs who have demonstrated technical expertise and proven customer success in DevOps and specialized solution areas like Continuous Delivery. DevOps Competency Partners provide solutions to, or have deep experience working with AWS users and other businesses to help t...
SYS-CON Events announced today that Super Micro Computer, Inc., a global leader in high-performance, high-efficiency server, storage technology and green computing, will exhibit at the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. Supermicro (NASDAQ: SMCI), the leading innovator in high-performance, high-efficiency server technology is a premier provider of advanced server Building Block Solutions® for Data ...
The Internet of Things (IoT) is growing rapidly by extending current technologies, products and networks. By 2020, Cisco estimates there will be 50 billion connected devices. Gartner has forecast revenues of over $300 billion, just to IoT suppliers. Now is the time to figure out how you’ll make money – not just create innovative products. With hundreds of new products and companies jumping into the IoT fray every month, there’s no shortage of innovation. Despite this, McKinsey/VisionMobile data...
DevOps has often been described in terms of CAMS: Culture, Automation, Measuring, Sharing. While we’ve seen a lot of focus on the “A” and even on the “M”, there are very few examples of why the “C" is equally important in the DevOps equation. In her session at @DevOps Summit, Lori MacVittie, of F5 Networks, will explore HTTP/1 and HTTP/2 along with Microservices to illustrate why a collaborative culture between Dev, Ops, and the Network is critical to ensuring success.